Ownership and insider activity for Labcorp Holdings Inc. (LH): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Price
| Price | $367.79 (closing price, November 4, 2026) |
| Market Cap | $29.8B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Oyegunwa Akinbolade | A-Award | 750 | |
| 2026-09-01 | Meltzer Jonathan C | A-Award | 900 | |
| 2026-09-01 | Vaughn Bryan T | A-Award | 1,500 | |
| 2026-09-01 | Caveney Brian J | A-Award | 3,000 | |
| 2026-08-17 | ANDERSON KERRII B | S-Sale | 3,000 | $954K |
| 2026-08-11 | Schechter Adam H | S-Sale | 4,669 | $1.5M |
| 2026-08-04 | Summy Amy B. | S-Sale | 924 | $283K |
| 2026-08-03 | Wilkinson Peter J | M-Exempt | 1,338 | $280K |
| 2026-08-03 | Wilkinson Peter J | S-Sale | 82 | $25K |
| 2026-08-03 | Wilkinson Peter J | S-Sale | 1,338 | $414K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $433.6M | $316.6M | $426.8M | $337.5M | $1.32B | $1.47B | $320.6M | $536.8M | $1.52B | $532.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.52B | $1.85B | $1.86B | $2.03B | $3.02B | $2.98B | $2.00B | $2.10B | $2.10B | $2.26B |
| Inventory | $205.2M | $227.6M | $237.3M | $244.7M | $423.2M | $401.4M | $470.6M | $474.6M | $493.2M | $534.7M |
| Total Current Assets | $2.48B | $2.68B | $2.84B | $2.98B | $5.13B | $5.33B | $4.62B | $3.77B | $4.81B | $4.02B |
| Property, Plant & Equipment | $1.72B | $1.75B | $1.78B | $2.61B | $2.73B | $2.82B | $2.79B | $2.91B | $3.05B | $3.08B |
| Goodwill | $6.42B | $7.53B | $7.36B | $7.87B | $7.75B | $7.96B | $6.12B | $6.14B | $6.37B | $6.79B |
| Intangible Assets | $3.40B | $4.34B | $3.91B | $4.03B | $3.96B | $3.74B | $3.12B | $3.34B | $3.49B | $3.60B |
| Total Assets | $14.25B | $16.57B | $16.19B | $18.02B | $20.07B | $20.39B | $20.16B | $16.73B | $18.38B | $18.39B |
| Accounts Payable | $508.4M | $573.9M | $634.6M | $632.3M | $638.9M | $621.3M | $852.2M | $827.5M | $875.8M | $840.8M |
| Short-term Debt | $541.1M | $409.2M | $10.0M | $415.2M | $376.7M | $1.5M | $301.3M | $999.8M | $1.00B | $695.8M |
| Total Current Liabilities | $1.83B | $2.19B | $1.88B | $2.66B | $3.08B | $2.78B | $3.08B | $3.23B | $3.33B | $2.82B |
| Long-term Debt | $5.24B | $6.29B | $5.99B | $5.79B | $5.42B | $5.42B | $5.04B | $4.05B | $5.33B | $5.77B |
| Total Liabilities | $8.73B | $9.85B | $9.19B | $10.46B | $10.61B | $10.09B | $10.04B | $8.83B | $10.31B | $9.76B |
| Retained Earnings | $4.96B | $6.22B | $7.08B | $7.90B | $9.48B | $10.46B | $10.58B | $7.89B | $8.30B | $8.64B |
| Total Equity | $5.51B | $6.80B | $6.97B | $7.57B | $9.44B | $10.27B | $10.10B | $7.88B | $8.05B | $8.62B |
| Total Debt | $5.85B | $6.76B | $6.06B | $7.11B | $6.76B | $6.34B | $6.25B | $5.95B | $7.27B | $7.20B |
| Net Debt | $5.42B | $6.45B | $5.63B | $6.77B | $5.44B | $4.87B | $5.93B | $5.42B | $5.75B | $6.67B |
| Working Capital | $651.1M | $496.9M | $956.5M | $325.4M | $2.05B | $2.55B | $1.55B | $540.2M | $1.48B | $1.20B |
Financial Health
| Debt / Equity | 0.77 |
| Current Ratio | 1.41 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 3.05 |
Profitability
| Return on Equity | 11.54% |
| Return on Invested Capital | 7.88% |
| Return on Assets | 5.31% |
| Gross Margin | 27.95% |
| Operating Margin | 11.12% |
| Net Margin | 6.88% |
Related companies: NTRA · GH · GRAL · TMO · DGX · QGEN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of LH: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks